Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: Results from a claims-based inception cohort study

World Psychiatry

Volumn 14, Issue 1, 2015, Pages 56-63

  Correll, Christoph U ^a,b,c,d   Joffe, Benjamin I ^e   Rosen, Lisa M ^c   Sullivan, Timothy B ^d,f   Joffe, Russell T ^b,d,g  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^e Howard Hughes Medical Institute   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

coronary heart disease; diabetes mellitus; essential hypertension; hyperlipidemia; hypertensive heart disease; Second generation antipsychotics; stroke

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR RISK FACTOR; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOOD DISORDER; OBESITY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

EID: 84922900972     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20187     Document Type: Article

References (46)

1. Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35: 187-91.
2. Kane JM, Correll CU,. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71: 1115-24.
3. Sankaranarayanan J, Puumala SE,. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Ther 2007; 29: 723-41.
4. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-62.
5. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-71.
6. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
7. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013; 10: 1-24.
8. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011; 20: 177-84.
9. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359-69.
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
11. Newcomer JW,. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 1): 1-93.
12. Ward A, Quon P, Abouzaid S, et al. Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a Medicaid population: clinical and economic evaluation. P T 2013; 38: 109-15.
13. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8: 114-26.
14. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-72.
15. Correll CU, Lencz T, Malhotra AK,. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17: 97-107.
16. Nielsen J, Skadhede S, Correll CU,. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010; 35: 1997-2004.
17. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26: 144-58.
18. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-73.
19. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-7.
20. Brauer R, Douglas I, Smeeth L,. The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. Br J Clin Pharmacol 2011; 72: 871-8.
21. Kleijer BC, Koek HL, van Marum RJ, et al. Risk of acute coronary syndrome in elderly users of antipsychotic drugs: a nested case-control study. Heart 2012; 98: 1166-71.
22. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17: 617-29.
23. Wooltorton E,. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-70.
24. Herrmann N, Lanctot KL,. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 91-103.
25. Sacchetti E, Trifiro G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22: 39-46.
26. Herrmann N, Mamdani M, Lanctot KL,. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5.
27. Sacchetti E, Turrina C, Cesana B, et al. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. J Psychopharmacol 2010; 24: 1131-2.
28. Shin JY, Choi NK, Jung SY, et al. Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study. J Psychopharmacol 2013; 27: 638-44.
29. Percudani M, Barbui C, Fortino I, et al. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 2005; 25: 468-70.
30. Mittal V, Kurup L, Williamson D, et al. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26: 10-28.
31. Wooltorton E,. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395.
32. Wu CS, Wang SC, Gau SS, et al. Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 2013; 73: 414-21.
33. Douglas IJ, Smeeth L,. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227.
34. Layton D, Harris S, Wilton LV, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol 2005; 19: 473-82.
35. Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol 2009; 23: 909-14.
36. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445.
37. Pratt NL, Roughead EE, Ramsay E, et al. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series. Drugs Aging 2010; 27: 885-93.
38. Sacchetti E, Turrina C, Valsecchi P,. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf 2010; 33: 273-88.
39. Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69: 1247-56.
40. Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med (in press).
41. Niranjan A, Corujo A, Ziegelstein RC, et al. Depression and heart disease in US adults. Gen Hosp Psychiatry 2012; 34: 254-61.
42. Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 2011; 306: 1241-9.
43. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199: 99-105.
44. Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42: 125-47.
45. Pratt LA, Brody DJ,. Depression and smoking in the U.S. household population aged 20 and over, 2005-2008. NCHS Data Brief 2010; 34: 1-8.
46. Diaz F, James D, Botts S, et al. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia and major depression. Bipolar Disord 2009; 11: 154-65.